Drug Trial Radar · NCT05020678
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Aug 20, 2021
Primary completion
Mar 31, 2025
Study completion Dec 2038
Sponsor
- Lead sponsor
- Nkarta, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)
Conditions
- Lymphoma, Non-Hodgkin
- B-cell Acute Lymphoblastic Leukemia
- Large B-cell Lymphoma
- Mantle Cell Lymphoma
- Indolent Lymphoma
- Waldenstrom Macroglobulinemia
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Aggressive Lymphoma
- Large-cell Lymphoma
Interventions
NKX019Biological
NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 × 10\^8 NK cells (6 × 10\^6/kg for patients \< 50 kg) administered as 3 weekly doses. Part 2 (dose expansion cohorts) will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: 30 days after last dose of NKX019
- Proportion of subjects experiencing dose-limiting toxicities of NKX019Time frame: 28 days from first dose of NKX019
- Objective response rate to NKX019 in Part 2Time frame: Primary assessment: 28 days after the first dose of NKX019 followed up to 2 years after the last dose of NKX019]
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Colorado Blood Cancer Institute
Denver, Colorado
The Cleveland Clinic Foundation
Cleveland, Ohio
Institute of Haematology, Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
St. Vincent's Hospital
Sydney, New South Wales, Australia
Royal Brisbane and Woman's Hospital
Brisbane, Queensland, Australia
Peter MacCallum Cancer Center
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.